Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which ...

Pharmaceutical company Eli Lilly has announced plans to acquire private biotech company SiteOne in a deal worth up to $1 ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines ...

Eli Lilly and Co. announced plans on Tuesday to acquire private biotechnology company San Francisco-based SiteOne ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

The deal prepares for a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from ...

Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% ...

In the marketing effort promoting Lilly’s Mounjaro, Stonestreet and his mother, Jamey, discuss living with type 2 diabetes and taking the GLP-1 for treatment.

The U.S. imports more pharmaceutical products from Ireland than from any other country -- nearly $50 billion last year. It won't be surprising if the Trump administration especially targets those ...

Eli Lilly and Company (NYSE:LLY) is expanding its footprint into the non-opioid pain management market in pursuit of growth ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...